Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 6/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.37 |
| ▸ | FDPS | P14324 | 9/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9156566 | 1.00 | GGPS1 (0.38) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL11636364 | 1.00 | GGPS1 (0.38) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL11065631 | 0.82 | TSHR (0.38) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL9156559 | 0.82 | TSHR (0.38) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL11636360 | 0.82 | TSHR (0.38) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL1921065 | 0.81 | LMNA (0.31) | — | |
| SCHEMBL10390922 | 0.80 | GGPS1 (0.39) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL11611962 | 0.78 | GGPS1 (0.38) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL271122 | 0.78 | GGPS1 (0.38) | GGPS1SMPD1FDPSCES2LPAR1 | |
| SCHEMBL270050 | 0.78 | GGPS1 (0.38) | GGPS1SMPD1FDPSCES2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002313-A1 | [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2024-01-04 | — | — | US | disclosed |
| CN-117098749-A | [11C] Labeled acyclic retinoids, central nervous system activators and methods for their manufacture | 国立研究开发法人国立长寿医疗研究中心 | 2023-11-21 | — | — | CN | disclosed |
| EP-4249058-A1 | [11C]-LABELLED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | National Center for Geriatrics and Gerontology (JP) | 2023-09-27 | — | — | EP | disclosed |
| US-5600034-A | HEAT TREATING DIALLYL ETHERS IN PRESENCE OF CATALYST CONTAINING PALLADIUM AND PHOSPHORUS COMPOUNDS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-02-04 | — | — | US | disclosed |
| US-5583271-A | Method for continuously producing alkadienols | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002313-A1 | [11C]-LABELED ACYCLIC RETINOID, CENTRAL NERVOUS SYSTEM ACTIVATOR, AND PRODUCTION METHODS FOR SAME | NR2E3, FABP7, RARB | GGPS1 2819/4885SMPD1 2805/4885FDPS 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.